Rohit Divekar1, John Hagan2, Matthew Rank3, Miguel Park2, Gerald Volcheck2, Erin O'Brien4, Jeffrey Meeusen5, Hirohito Kita2, Joseph Butterfield2. 1. Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, Minn. Electronic address: Divekar.Rohit@mayo.edu. 2. Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, Minn. 3. Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Scottsdale, Ariz. 4. Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minn. 5. Laboratory Medicine and pathology, Mayo Clinic, Rochester, Minn.
Abstract
BACKGROUND: Urinary leukotriene E4 (LTE4) is a well-validated marker of the cysteinyl leukotriene pathway, and LTE4 elevation has been described in conditions such as asthma, aspirin sensitivity, and chronic rhinosinusitis (CRS). There have been a number of reports investigating the role of spot urine LTE4 to predict aspirin sensitivity; however, variability in urinary LTE4 may affect the accuracy of this approach. OBJECTIVE: Here, we explored the utility of 24-hour urinary LTE4 in 5 clinical diagnoses of allergic rhinitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), CRS without nasal polyps, and aspirin sensitivity. METHODS: This was a retrospective review of patients who had 24-hour quantification of urinary LTE4 by a clinically validated liquid chromatography tandem mass spectrometry method and their assigned diagnoses after assessment and clinical care. RESULTS: Twenty-four-hour urinary LTE4 elevations were seen in those with asthma and those with CRSwNP but influenced by underlying aspirin sensitivity. Elevation in LTE4 was significant in those with CRSwNP after adjusting for aspirin sensitivity. Allergic rhinitis was not associated with elevated LTE4 excretion. Receiver operator characteristic analysis of 24-hour urinary LTE4 showed that a cutoff value of 166 pg/mg Cr suggested the presence of history of aspirin sensitivity with 89% specificity, whereas a cutoff value of 241 pg/mg Cr discriminated "challenge-confirmed" aspirin-sensitive subjects with 92% specificity. CONCLUSIONS: Elevated 24-hour excretion of urinary LTE4 is a reliable and simple test to identify aspirin sensitivity in patients with respiratory diagnoses.
BACKGROUND: Urinary leukotriene E4 (LTE4) is a well-validated marker of the cysteinyl leukotriene pathway, and LTE4 elevation has been described in conditions such as asthma, aspirin sensitivity, and chronic rhinosinusitis (CRS). There have been a number of reports investigating the role of spot urine LTE4 to predict aspirin sensitivity; however, variability in urinary LTE4 may affect the accuracy of this approach. OBJECTIVE: Here, we explored the utility of 24-hour urinary LTE4 in 5 clinical diagnoses of allergic rhinitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), CRS without nasal polyps, and aspirin sensitivity. METHODS: This was a retrospective review of patients who had 24-hour quantification of urinary LTE4 by a clinically validated liquid chromatography tandem mass spectrometry method and their assigned diagnoses after assessment and clinical care. RESULTS: Twenty-four-hour urinary LTE4 elevations were seen in those with asthma and those with CRSwNP but influenced by underlying aspirin sensitivity. Elevation in LTE4 was significant in those with CRSwNP after adjusting for aspirin sensitivity. Allergic rhinitis was not associated with elevated LTE4 excretion. Receiver operator characteristic analysis of 24-hour urinary LTE4 showed that a cutoff value of 166 pg/mg Cr suggested the presence of history of aspirin sensitivity with 89% specificity, whereas a cutoff value of 241 pg/mg Cr discriminated "challenge-confirmed" aspirin-sensitive subjects with 92% specificity. CONCLUSIONS: Elevated 24-hour excretion of urinary LTE4 is a reliable and simple test to identify aspirin sensitivity in patients with respiratory diagnoses.
Authors: Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt Journal: J Clin Epidemiol Date: 2003-11 Impact factor: 6.437
Authors: Monika Świerczyńska-Krępa; Marek Sanak; Grażyna Bochenek; Paweł Stręk; Adam Ćmiel; Anna Gielicz; Hanna Plutecka; Andrzej Szczeklik; Ewa Niżankowska-Mogilnicka Journal: J Allergy Clin Immunol Date: 2014-04-24 Impact factor: 10.793
Authors: Marcus Shaker; Ano Lobb; Pamela Jenkins; Daniel O'Rourke; Steve K Takemoto; Salil Sheth; Thomas Burroughs; Mark S Dykewicz Journal: J Allergy Clin Immunol Date: 2007-08-22 Impact factor: 10.793
Authors: K Asano; C M Lilly; W J O'Donnell; E Israel; A Fischer; B J Ransil; J M Drazen Journal: J Allergy Clin Immunol Date: 1995-11 Impact factor: 10.793
Authors: Elina Jerschow; Matthew L Edin; Yuling Chi; Beth Hurst; Waleed M Abuzeid; Nadeem A Akbar; Marc Gibber; Marvin P Fried; Weiguo Han; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; Fred B Lih; Artiom Gruzdev; J Alyce Bradbury; Victor Schuster; Simon Spivack; David Rosenstreich; Darryl C Zeldin Journal: J Allergy Clin Immunol Pract Date: 2018-12-21
Authors: Suzy A A Comhair; Grazyna Bochenek; Sara Baicker-McKee; Zeneng Wang; Tomasz Stachura; Marek Sanak; Jeffrey P Hammel; Stanley L Hazen; Serpil C Erzurum; Ewa Nizankowska-Mogilnicka Journal: Respir Res Date: 2018-10-30